<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684008</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-107-08</org_study_id>
    <secondary_id>MSKCC IRB #07-127</secondary_id>
    <nct_id>NCT00684008</nct_id>
  </id_info>
  <brief_title>Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant</brief_title>
  <official_title>A Phase I Study of CYT107 (Recombinant Glycosylated Human IL-7) in Recipients of HLA Matched Ex Vivo T Cell Depleted Bone Marrow or Peripheral Blood Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytheris, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytheris, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I inter-patient dose escalation open labeled study assessing multiple doses
      of CYT107 in patients of at least 15 years of age, who are recipients of HLA matched ex vivo
      T cell depleted bone marrow or peripheral blood stem transplants.

      The dose escalation design is aimed at establishing the absence of significant toxicity and
      to define a biologically active dose in this patient population.

      At each dose level, eligible patients will receive 3 doses of CYT107 injected subcutaneously
      (under the skin of the arm, legs, or stomach) once a week for 3 weeks.

      Groups of three patients will be entered at each dose level of CYT107. Three dose levels are
      planned: 10 mcg/kg/week, 20 mcg/kg/week and 30 mcg/kg/week. Three patients must complete day
      42 of the study at a dose level without a dose limiting toxicity (DLT) before there is
      escalation to the next dose level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Delayed and deficient reconstitution of T cells and their functions are a major
      obstacle to the success of a hematopoietic stem cell transplant (HSCT). CYT-107 may have
      potential clinical use after allogeneic HSCT to enhance lymphoid reconstitution which could
      have a number of beneficial effects including decreased morbidity and mortality from
      post-transplant infections. Our preliminary data with a previous generation IL-7, CYT 99 007,
      raise the possibility that IL-7 could have, in some cases, an anti-GVHD effect while keeping
      the anti-tumor effect of the allograft intact.

      Primary Objective:

        -  To determine the safety and a recommended dose of CYT107 (r-hIL-7) in recipients of an
           HLA-matched related or unrelated ex vivo T-cell-depleted bone marrow (BM) or peripheral
           blood stem cell (PBSC) transplant after initial engraftment and hematopoietic
           reconstitution.

        -  If toxicities are encountered, to establish the maximum tolerated dose (MTD) and dose
           limiting toxicities (DLT).

      Secondary Objectives:

        -  To define the pharmacokinetics of escalating doses of CYT107 in recipients of allogeneic
           transplants.

      To achieve preliminary characterization:

        -  Of the effects of CYT107 treatment on engraftment and GVHD.

        -  Of the effects of CYT107 on the recovery of T, NK and B cell populations and their
           functions in vitro.

        -  Of a tolerable biologically active range of doses for CYT107 in recipients of allogeneic
           transplants.

        -  Whether and to what degree administration of CYT107 might influence the risk of
           developing an EBV-lymphoproliferative disorder.

        -  Of the effects of CYT107 treatment on leukemia relapse.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity of CYT107 in post-transplant patients with AML, CML and MDS using the NCI Common Toxicity Criteria version 3.0 with the BMT specific adverse event grading system.</measure>
    <time_frame>Visits: 2 week screening period; treatment visits on days 0, 7, and 14; non-treatment visits on Days 1, 21, 28, 42, 56, and 77.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and Pharmacodynamics</measure>
    <time_frame>Study days 0, 1, 7, 14, 21, 28, 42, and 77.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>AML</condition>
  <condition>CML</condition>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm dose escalation study. Three successive cohorts of 3 patients each. Doses to be evaluated: 10, 20, and 30 mcg/kg/dose for 3 consecutive doses.
CYT107 is a recombinant protein belonging to the class of growth factors known as cytokines.
CYT107 is a heavily glycosylated and sialylated form of recombinant human Interleukin-7.
CYT107 is supplied as a sterile colorless liquid at a concentration of 4 mg/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT107 - Recombinant glycosylated human interleukin 7.</intervention_name>
    <description>Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.</description>
    <arm_group_label>I</arm_group_label>
    <other_name>rhIL-7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhIL-7 (CYT107)</intervention_name>
    <description>10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.</description>
    <arm_group_label>I</arm_group_label>
    <other_name>interleukin-7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to read consent form and give informed consent.

          -  At least 15 years old.

          -  Histologically confirmed non-lymphoid hematological malignancy.

          -  Recipient of T cell depleted bone marrow (BM) or peripheral blood stem cell (PBSC)
             transplant from a 6/6 HLA (A, B, DR by intermediate resolution) identical related or
             unrelated donor after myeloablative conditioning.

          -  Received TCD HCT containing &lt; 1x105 CD3+ T cells/kg of recipient.

          -  Patient included in at least one of the following categories:

               -  AML in 2nd or greater complete remission.

               -  High-risk AML (high-risk cytogenetics, undifferentiated leukemia, secondary AML,
                  antecedent MDS) in 1st remission.

               -  CML in 2nd or greater chronic phase, 2nd or greater accelerated phase.

               -  MDS intermediate or high risk by IPSS criteria.

          -  History of opportunistic infection (CMV viremia requiring anti-viral therapy, PCP
             pneumonia, mycobacterial infection, herpes zoster, viral respiratory infection
             (influenza, RSV, para-influenza), etc.

          -  CD4+ T cell count &lt; 100 at 6 months post-transplant.

          -  At high risk for opportunistic infection (e.g., history of treated invasive fungal
             infection prior to the transplantation, positive CMV serology in patient, or positive
             toxoplasmosis serology in donor and patient, etc.).

          -  60 - 210 days post transplant.

          -  In remission at the time of initiation of CYT107.

          -  Documented engraftment with sustained neutrophil counts of at least 1000/mcl and
             untransfused platelet counts &gt; 20 000/mcl for 3 consecutive lab values (the last one
             tested &lt;10 days before initiation of treatment) on 3 different days prior to
             treatment. Patients who have engrafted but require G-CSF for myelosuppressive
             antibiotics or antiviral medications are eligible if they require G-CSF no more than
             twice weekly and their ANC remains &gt;1000/mcl.

          -  KPS &gt; 60%.

          -  Adequate organ function:

               -  Cardiac: No evidence of change in cardiac function by history, exam and/or EKG
                  post-HCT.

               -  Pulmonary: Absence of dyspnea or hypoxia (&lt; 90% of saturation by pulse oxymetry
                  on room air).

               -  Hepatic: Bilirubin &lt;= 1.5 X ULN, AST (SGOT) and /or ALT (SGPT) &lt;= 2.5 X ULN.
                  PT/PTT &lt; 1.5 X ULN.

               -  Renal: Calculated Creatinine clearance &gt; 60 mL/min/1.73 m2. [Note: all transplant
                  patients had an ejection fraction of &gt; 40% on their pre-transplant echocardiogram
                  and a DLCO &gt; 50% of predicted (corrected for hemoglobin)]

        Exclusion Criteria:

          -  No evidence or history of acute GVHD or of chronic GVHD.

          -  No recurrent leukemia post HCT.

          -  No active uncontrolled viral, bacterial or fungal infection.

          -  No documented HIV-1 or -2, HBV or HCV infection at any time before or after transplant
             (a positive hepatitis B serology indicative of a previous immunization is not an
             exclusion criteria).

          -  Not be receiving systemic corticosteroid, anti-mitotic agent or other
             immunosuppressive treatment.

          -  Not receiving Growth Hormone or gonadotropin agonists/ antagonists.

          -  Not receiving any cytokine support other than G-CSF post-HCT.

          -  Not receiving concurrent treatment with another investigational drug and/or biological
             agent.

          -  Not receiving anticoagulant therapy.

          -  No uncontrolled hypertension.

          -  No history of lymphoid malignancy (e.g. Hodgkin disease, non Hodgkin lymphoma, Acute
             Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia) or acute biphenotypic
             leukemia.

          -  No peripheral lymphadenopathy (any lymph node &gt; 1 cm).

          -  No history of EBV associated lymphoproliferation.

          -  No EBV viremia equal to or greater than 500 copies EBV DNA/mL of blood by quantitative
             PCR.

          -  No history of autoimmune disease nor a HCT donor with a history of an autoimmune
             disease.

          -  Fertile patients must use effective birth control. Not pregnant or nursing. Negative
             pregnancy test within 2 weeks of study treatment.

          -  QTc prolongation (QTc &gt; 470 ms) or prior history of significant arrhythmia or ECG
             abnormalities.

          -  No active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements.

          -  Any past or current psychiatric illness that, in the opinion of the investigator,
             would interfere with adherence to study requirements or the ability and willingness to
             give written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcel van den Brink, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alpdogan O, Muriglan SJ, Eng JM, Willis LM, Greenberg AS, Kappel BJ, van den Brink MR. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2003 Oct;112(7):1095-107.</citation>
    <PMID>14523046</PMID>
  </reference>
  <reference>
    <citation>Rosenberg SA, Sport√®s C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006 May-Jun;29(3):313-9.</citation>
    <PMID>16699374</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>Marcel R.M. van den Brink, M.D., Ph.D.</name_title>
    <organization>Memorial Sloan-Kettering Cancer Center</organization>
  </responsible_party>
  <keyword>interleukin-7</keyword>
  <keyword>immune based therapies</keyword>
  <keyword>graft vs host disease</keyword>
  <keyword>immune reconstitution</keyword>
  <keyword>infection</keyword>
  <keyword>lymphopenia</keyword>
  <keyword>hematopoetic stem cell transplantation</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>peripheral blood stem cell transplant</keyword>
  <keyword>immunosuppression</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

